The most recent guidelines for magnetic resonance imaging (MRI) in multiple sclerosis (MS) recommend three-dimensional (3D) MRI sequences over their two-dimensional (2D) counterparts. This development has been made possible by advances in MRI scanner hardware and software. In this article, we review the 3D versions of conventional sequences, including T1-weighted, T2-weighted and fluid-attenuated inversion recovery (FLAIR), as well as more advanced scans, including double inversion recovery (DIR), FLAIR 2 , FLAIR*, phase-sensitive inversion recovery, and susceptibility weighted imaging (SWI).
Introduction
In Multiple sclerosis (MS), early diagnosis and initiation of therapy, as well as efficient escalation of therapy are key to preventing long-term disability. 1 Radiological disease activity is known to predict long-term disability especially in early MS. 1 Magnetic resonance (MR) modalities currently used in clinical settings mostly evaluate white matter lesions which are well characterized in MS and exhibit a typical pattern of morphology, distribution, and signal. 2, 3 However, gray matter lesion load and brain atrophy may be better correlated to disability and cognitive impairment than white matter lesion load. 4, 5 Furthermore, a variety of advanced magnetic resonance imaging (MRI) measures have shown that myelin and axon damage in normal-appearing white matter (NAWM) correlate with disease severity. 6, 7 The general MRI protocol for MS involves imaging the brain and the spinal cord using four conventional MRI sequences: T1-weighted, T2-weighted, T2 fluidattenuated inversion recovery (FLAIR), and post-single-dose gadolinium (Gd)-enhanced T1-weighted scan. Currently, the standard protocol for MS allows for limited assessment of brain atrophy, gray matter lesions, and pathology in NAWM, which all appear clinically relevant. Consequently, there is a need for implementing new imaging techniques in MS assessment and monitoring. Traditionally, brain and spinal cord imaging have been acquired using two-dimensional (2D) sequences, with the exception of a three-dimensional (3D) T1-weighted scan for volume and cortical thickness. Initially, acquisition times of 3D scans were long due to the large number of phase encoding steps. As better coil technology and parallel imaging have become widely available, whole-brain 3D scans with spatial resolution of 1 mm 3 can be acquired in 3 to 8 minutes and are now recommended whenever possible. 8 In this review, we give an overview of the strengths and limitations of conventional and advanced 3D MRI in MS, highlighting its potential for improving diagnosis and monitoring.
General advantages of 3D-MRI vs 2D-MRI
3D scans have various advantages over their 2D counterparts. Since images acquired through 3D scans can have isotropic (same length along all three directions) voxels and as there are no interslice gaps by definition, 3D scans can be easily reformatted without compromising image quality. 9,10 The 3D scans are typically acquired in sagittal orientation. This allows for parallel imaging acceleration along the left-right and the anterior-posterior directions. 11 Since the entire head is scanned, no slice oversampling is required, which saves around 15% of scan time. Furthermore, 3D scans allow for additional acceleration using compressed sensing. 12, 13 Figure 1(a) shows sagittally acquired 3D T2, (b) 3D FLAIR, and a combination of the two called FLAIR 2 (FLAIR square) 14 in Figure 1 (c) from a 3 Tesla (3 T) system using an Three-dimensional MRI sequences in MS diagnosis and research eight-channel head coil and parallel imaging along the left-right and anterior-posterior directions. For comparison, Figure 1 (d) shows a 3D FLAIR in a different patient acquired on a current 3 T system equipped with a 32-channel head coil, using a combination of parallel imaging 11 and compressed sensing. 12 While typical spatial resolutions are around 1 mm 3 , at 3 T and with current coil technology, voxel volumes of 0.5 mm 3 can be acquired within reasonable times. Whole-brain scans acquired in 3D also provide for better image registration between different time points or between different 3D scans from the same session. 2D scans, in particular 2D FLAIR, can have artifacts from cerebrospinal fluid (CSF) and inflowing blood in infratentorial regions. 14 Due to the non-selective inversion pulses in 3D FLAIR sequences, on the other hand, there are no artifacts from the inflow of non-inverted blood and CSF. Furthermore, 2D scans have slices thicknesses of 3 mm or more, and an additional sagittal scan is often required to reliably detect lesions in the corpus callosum. Such scan is not needed with 3D scans.
In general, studies have found that 3D modalities outperform their 2D counterparts in terms of detection of lesions in all areas of the brain and spine, detection of lesions of smaller size, and image quality in terms of contrast-to-noise ratio (CNR) and flow artifacts. There is also no need for complementary scans (e.g. separate saggital and axial FLAIR requisitions), as 3D scans capture the entire brain. 3D MRI offers greater spatial resolution and detects more lesions than 2D MRI, resulting in a better comparison of disease status across time. In being more sensitive in lesion detection, 15 3D MRI could allow for earlier fulfillment of the dissemination in time and dissemination in space components of the McDonald criteria. 8 By better detecting newly active lesions, 16 3D MRI can lead to a more efficient identification new of disease activity and thus an earlier diagnosis of MS (dissemination in time) or more prompt escalation of therapy. 1 Better detection of active lesions could also permit better confirmation of disease activity, as it is sometimes challenging to clinically differentiate between relapses and other causes of symptom , using a Philips Achieva 3T system equipped with an eight-channel SENSE head coil. (d) 3D FLAIR with the same acquired and reconstructed voxel size in a different patient and scanned on a current Philips Elition 3T system equipped with a 32-channel head coil using a combined SENSE/compressed sensing acceleration factor of 9, resulting in a data acquisition time of 5:12 minutes at a TR of 8000 ms and a TI of 2400 ms.
exacerbation. 17 Another clinical advantage of 3D MRI is that it could allow for a more accurate diagnosis of MS, either through better visualization of cortical lesions, 18 now included in the revised 2017 McDonald diagnostic criteria, with 3D double inversion recovery (DIR) or FLAIR 2 , or the evaluation of the central vein sign using susceptibility weighted imaging (SWI) in combination with FLAIR. 19 Both cortical lesions and a high percentage of lesions with a central vein sign are more specific for MS and allow differentiation from MS mimics, such as neuromyelitis optica spectrum disorder. 20 Moreover, cerebral atrophy and burden of cortical lesions correlate better than white matter lesions with cognitive impairment and disability, and could become new treatment targets, 21, 22 for which the use of 3D MRI would be paramount.
T2-weighted MRI
T2-weighted MRI is a basic pulse sequence which highlights differences in T2 relaxation time. An MS lesion is an environment with increased water content, making it bright on T2-weighted MRI. 2D T2-weighted techniques have been investigated as potential markers for clinical MS progression, and it has been shown to be a useful marker of ongoing disease activity as lesion load tends to increase over time as disease progresses. 23, 24 However, studies on focal white matter pathology have generally shown only low to moderate correlation between lesion load on 2D T2 and clinical measures of disease. 4, 25 Furthermore, although T2-weighted MRI is the most sensitive modality for detecting MS plaques and the best sequence for detecting lesions in the posterior fossa, 2D T2 spin echo (SE) imaging is relatively insensitive for detecting MS lesions in various areas of the brain, especially cortical gray matter. 26 In addition, T2-weighted MRI is unable to differentiate between acute and chronic lesions and is not specific for the degree of myelin and axon loss. 27 With its use of contiguous thin partitions, 3D T2 achieves higher spatial resolution than 2D T2 sequences 11 and provides the general advantages-related reformatting, image registration, discussed in the previous section. However, there is limited research comparing 2D and 3D T2 sequences in the evaluation of MS. With a spatial resolution of 1.9 mm 3 at 1.5 T, Moraal et al. 28 found no improvement when comparing 3D T2 and 2D T2 sequences and found no significant difference in the total cortical and white matter lesions between the two scans. It should be noted that current 3 T scanners, which can easily achieve spatial resolutions of 1 mm 3 or better for 3D T2 scans, may reveal improvement of 3D T2 over 2D T2 scans.
FLAIR
FLAIR is a heavily T2-weighted sequence with inversion pulse played before the imaging part of the scan. The time delay between the inversion pulse and the excitation pulse of the imaging part of the FLAIR scan, the inversion time, is chosen so that CSF is selectively nulled. 29 This CSF nulling approach enhances the contrast between the bright MS lesions and the now dark CSF, at the cost of an overall reduction in signal-to-noise ratio (SNR) and an increase in scan time compared to standard T2-weighted MRI. 30, 31 2D FLAIR usually involves brain sections parallel to the subcallosal line. Due to slice thicknesses of 3 mm or more, an additional sagittal 2D FLAIR scan is required for the detection of lesions in the corpus callosum. 30, 32 Moreover, in infratentorial areas, 2D FLAIR is affected by CSF and blood flow artifacts, and often has insufficient T2-weighting, requiring additional proton density or T2-weighted images for complete coverage of all brain regions. Finally, an interslice gap of about 1.5 mm is typically used in these 2D scans which may reduce conspicuity of some small lesions. 33 Since 3D FLAIR is insensitive to flow artifacts, has thin partitions without gaps, and high isotropic spatial resolution, no additional acquisitions for the corpus callosum or infratentorial regions are needed. 34 3D FLAIR improves upon 2D FLAIR in many aspects relevant to the diagnosis and clinical investigation of MS, such as lesion detection 34 and CNR. Studies at 3 T found that 3D FLAIR revealed 21%-74% more lesions or white matter hyperintensities than 2D FLAIR. 33, 35, 36 This improvement was largely attributed to thinner slices and lack of interslice gaps in the 3D sequence, which allowed for the detection of smaller lesions. Furthermore, it was found that compared to 2D FLAIR, 3D FLAIR has higher CNR between lesions and CSF, lesions and white matter, and lesions and gray matter, as well as higher SNR in general. 15, 33, 34 Other studies have corroborated these findings and demonstrated that 3D FLAIR has a 63.8%-167.8% higher CNR and 68%-147.6% higher SNR across various anatomical locations. 9,36 Finally, 3D FLAIR sequences allow for multiplanar reformatting of acquired images in any plane, calculation of volumes, and displaying of surface anatomy. 9, 37, 38 Image acquisition times at 3 T ranges from 4 to 7 minutes compared to the 2 to 3 minutes for a 2D-FLAIR. 9,33
Detection of Gd-enhancing lesion Gd enhancement is associated with blood-brain barrier breakdown, reflecting ongoing inflammation characteristic of active MS lesions. 39 Gd-enhanced MRI aids in diagnosis and follow-up of MS, as it displays active lesions and allows inference of inactive lesions by comparison to other scans, thereby demonstrating disease activity through time. 2, 8 Up until recently, post-single-dose Gd-enhanced 2D T1-weighted SE was the primary scan used in MS. 8 However, it has been found that Gd-enhanced 3D T1-weighted gradient echo imaging is superior to Gd-enhanced 2D T1 SE in terms of lesion conspicuity, lesion count, smaller lesion detection (<5 mm diameter), reproducibility, SNR, and CNR. 16 3D T1-gradient echo imaging detected 26%-96% more lesions than 2D T1 SE while maintaining an identical distribution of Gd-enhancing lesions across the various brain locations. This significant increase in small lesions found was attributed to the 60% smaller voxel size on the 3D T1-gradient echo scan. Gd-enhanced 3D T1-gradient echo has therefore been recommended over 2D T1-SE in MS for its better detection rate and image reproducibility. 8, 16 3D T1-weighted volumetric MRI Accelerated brain atrophy is well documented in MS. 7, [40] [41] [42] [43] Annual tissue loss is around 0.5%-1% compared to 0.1%-0.3% in controls and occurs in all subtypes of MS. [44] [45] [46] Currently, 3D T1-weighted MRI is the most commonly used scan for measuring wholebrain volume, cortical thickness/volume, and deep gray matter volume as imaging markers of brain atrophy in MS. 47 The precision of current methods for computing MRI volumetric biomarkers depends on image resolution and contrast between white matter, gray matter, and/or CSF. Most current methods of processing MRI scans involve a key preprocessing step of reslicing input scans into 1 mm (or smaller) isotropic resolution. 48 Therefore, scans that are natively close to this resolution would suffer less interpolation blurring than scans with thicker slices, such as typical 2D T1 SE scans. For these reasons, 3D T1-weighted scans with good tissue contrast and 1 mm or better isotropic resolution are recommended for MRI volumetry in MS. These scans should be performed before Gd enhancement, as vessel enhancement interferes with volumetric quantification.
Advanced sequences
DIR and phase-sensitive inversion recovery DIR employs two inversion pulses in order to null both signal from CSF and white matter, with the aim to improve the detection of cortical lesions. DIR has poor SNR and greater propensity for pulsation artifacts in clinically relevant areas than FLAIR and T2 SE. 26, 49, 50 An additional drawback is that 3D DIR takes about 33% percent longer to acquire than 3D FLAIR. 49 The low SNR and the long scan times preclude the high spatial resolutions required for the imaging of the cortex, which is only 2-to 4-mm thick. The low degree of inflammation in cortical lesions and artifacts from CSF pulsation further reduce DIR's sensitivity to cortical lesions. Consequently, DIR's sensitivity to cortical lesions is only 18%, at a specificity of 90%, as shown in a post-mortem study. 51 However, that study found that DIR had 28% higher sensitivity in detecting mixed gray matter-white matter lesions, and a two-fold higher detection of intracortical lesions, compared to 3D FLAIR. While 3D DIR has consistently demonstrated better detection of cortical lesions than 2D and 3D T2-weighted and FLAIR scans, 18,28,50 DIR's overall low sensitivity calls for improved approaches for cortical lesions. 52 Two potential alternatives to DIR are FLAIR 2 (discussed below), 13 and phase-sensitive inversion recovery (PSIR). Several recent studies showed that PSIR outperforms DIR in terms of total number of cortical lesions detected. [52] [53] [54] A longitudinal study in progressive MS found that PSIR detected more lesions both at baseline (9.4 vs 7.2, p = 0.006) and in follow-up (10.5 vs 7.7, p = 0.007) than DIR. 52 Almost one-third of lesions that appeared cortical on DIR showed considerable white matter involvement or no cortical gray matter involvement at all on PSIR, 51 suggesting that 3D DIR is unable to reliably separate between leukocortical and juxtacortical lesions.
SWI and FLAIR* SWI has been gaining importance in MS due to its ability to visualize small veins within MS lesions. 19, 55, 56 The scan for SWI is a gradient echo MRI scan typically acquired in 3D, which allows for thin slices and high spatial resolution of around 0.25 mm 3 . Long echo times of (20-30 ms at 3 T) are used for increased susceptibility contrast. [57] [58] [59] A promising variation of SWI is the sagittal acquisition of segmented gradient echo planar data. 60 Due to the sagittal acquisition, parallel imaging acceleration can be applied along two directions, resulting in acceleration factors of 4 or higher. Two averages of this scan at spatial resolution of 0.17 mm 3 can be acquired in less than 4 minutes. The high spatial resolution and the heavy T2* weighting (TE = 25-35 ms) result in excellent visualization of veins, even without utilization of phase information. The small isotropic voxel size also has the advantage that artifacts due to background field inhomogeneities near tissue-air and tissue-bone interfaces are dramatically reduced. 61 Moreover, sagittal acquisition and whole-brain coverage allows for excellent results of image registration with other 3D sagittal scans.
Voxel-wise multiplication of a 3D susceptibility sensitive MRI scan with a coregistered 3D FLAIR scan results in an image called FLAIR*, 62, 63 which displays lesions and veins simultaneously. Due to the high spatial resolution of the susceptibility weighted scan, the FLAIR scan is best acquired in 3D. Evidence is accumulating rapidly that MS lesions are more often traversed by veins than non-MS white matter hyperintensities, such as those related to migraine or hypertension. 19, [64] [65] [66] [67] Two small studies have suggested the use of a 40% cut-off value to distinguish MS lesions (40% or more lesions are traversed by a central vein) from non-MS lesions. 66, 68 This is in keeping with another in vivo study which found that 80%-94% of periventricular MS lesions contain a central vein, which corresponds to >90% sensitivity and specificity. 3, 20 FLAIR* has been demonstrated to allow superior lesion-NAWM and NAWM-vein CNR compared to conventional 3D FLAIR and T2*-weighted segmented echo planar imaging. 62 These intralesional veins on FLAIR* images were found throughout the brain. One potential drawback is the lack of reference standard for conspicuity of veins or lesions. Ultimately, prospective clinical multicenter trials are needed to evaluate whether the central vein sign improves MS diagnosis. Furthermore, simplified radiological algorithms need to be established that require only the assessment of a subset of lesions, rather than all lesions.
Quantitative imaging based on SWI Advanced processing of SWI produces quantitative images that may be useful as markers of tissue damage and repair in clinical MS trials. 69 The phase of the SWI scan can be turned into maps of local resonance frequency or magnetic susceptibility, [70] [71] [72] [73] [74] which are sensitive to the magnetic properties of tissue. In a serial study with monthly scans over 6 months, Wiggermann et al. 75 showed that the formation of new MS lesions is accompanied with rapid increases in MR resonance frequency, which is computed from phase, followed by elevated frequency for at least 6 months. At the same time, frequency of non-lesional tissue and NAWM remained constant over the 6-month period. While increases in tissue magnetic susceptibility within MS lesions can be due to either an increase in paramagnetic iron or a loss in diamagnetic myelin, studies in post-mortem tissue found increased iron in less than 10% of all MS lesions. Most MS lesions exhibit loss of both iron and myelin. [76] [77] [78] [79] [80] A notable exception is rings consisting of iron-laden microglia/macrophages that encompass some MS lesions. 76, 81, 82 It has been shown that these iron rings are mainly found in slowly expanding lesions, rarely in inactive lesions, and hardly at all in remyelinated lesions. 76 In addition, plaques which had remyelinated were found to have hardly any ironladen rim surrounding them. Overall, this points to the possibility of iron-laden rims being a marker of chronic lesion expansion, which would indicate MS disease activity.
If the SWI scan is acquired with multiple echoes, maps of R2* relaxation can be computed. 83 Deep gray matter R2* was shown to be increased in MS compared to controls, 84 and to increase more rapidly during early MS, whereas atrophy occurs at a faster rate later in the disease. 85 Since R2* correlates well with deep gray matter iron concentration, 86 the increase in R2* is often interpreted as iron deposition in the deep gray matter. Recent research, however, has shown that these increases in R2* may be at least in part due to deep gray matter volume loss. 87 In white matter, R2* depends mainly on myelin and iron content 88 but also on the angle between the white matter fibers and the main magnetic field. 89, 90 If white matter fiber orientation is measured with a diffusion tensor scan, whole-brain myelin and iron can be determined by fitting a tissue model to the orientation-dependent R2* data. 91 
FLAIR 2
Coregistration and multiplication of a 3D T2-weighted and a 3D FLAIR scan results in an image called FLAIR 2 , which has contrast very similar to DIR but at much higher SNR and CNR, at no additional cost in scan time. 14 FLAIR 2 enhances areas of high signal on both the FLAIR and T2 images while suppressing areas of low signal on either of the scans (Figure 1 ). This allows for the CSF to remain hypointense due to its suppression in the FLAIR scan. 3D FLAIR 2 has 133% higher gray matter-white matter CNR and 31% higher lesion-white matter CNR than 3D FLAIR. 14 Since FLAIR 2 requires no additional scan time, the time saved by omitting DIR or PSIR for cortical lesions can be invested in higher spatial resolution of the FLAIR and T2-weighted scans. The method's high isotropic spatial resolution of typically 0.3 mm 3 allows for superior detection of corpus callosum lesions and possibly better distinction of cortical lesions from juxtacortical lesions. Possible artifacts that may arise due to imperfect image registration between FLAIR and the T2-weighted scan are easily identifiable and the FLAIR and T2 images can be viewed separately, if necessary. Denoising the FLAIR scan acquired for FLAIR 2 improves the SNR of the final FLAIR 2 , with minimal blurring of lesions or anatomical structures. 92 Conclusion 3D versions of MRI scans for MS will continue to replace their 2D counterparts. This process is mainly driven by improvements in MRI scanner technology, superior image quality of 3D scans, and additional information gained from the combination of scans (FLAIR*, FLAIR 2 ) and advanced post-processing for quantitative analyses (QSM, R2*).
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